# Daily Aspirin for Heart Attack and Stroke Prevention: Understanding the New USPSTF Guidance This article explains why the US Preventive Services Task Force (USPSTF) has updated its guidance on daily aspirin for heart attack and stroke prevention. The key takeaway: aspirin is no longer recommended for everyone — the new guidance calls for individual decision-making for adults aged 40–59 at increased heart risk and discourages aspirin for adults aged 60 and older who have not already had a heart attack or stroke. # Daily Aspirin for Heart Attack and Stroke Prevention: Understanding the New USPSTF Guidance ## Table of Contents - Key Points - Background: Why This Research Matters - The Early Promise of Aspirin: What Initial Studies Found - The 2016 USPSTF Recommendations: Aspirin's Earlier Role - The 2018 Landmark Trials: New Evidence Changes the Picture - The TIPS-3 Trial (2020): A Polypill Plus Aspirin Approach - The 2019 ACC/AHA Guidelines: A Shift Toward Caution - The 2021–2022 USPSTF Recommendation: The New Guidance - Clinical Implications: What This Means for Patients - Limitations: What This Guidance Can't Tell Us - Recommendations: Actionable Advice for Patients - Frequently Asked Questions - Source Information ## Key Points - USPSTF now discourages starting aspirin for primary prevention in adults aged 60 or older. - For adults 40–59 at increased heart risk, aspirin decisions should be individualized based on bleeding risk. - Aspirin reduces cardiovascular events but increases major bleeding, so the net benefit varies by person. - In the ASPREE trial, healthy older adults taking aspirin had higher overall and cancer-related death rates. - Aspirin remains recommended for secondary prevention after a heart attack, stroke, or stent placement. ## Background: Why This Research Matters Every day, millions of people take a low-dose aspirin hoping to prevent a first heart attack or stroke. This practice — known as **primary prevention** — refers to using a medication to prevent a first cardiovascular event in people who have no history of heart disease. Aspirin works by making blood platelets less sticky, reducing the chance a clot will form and block a blood vessel. But aspirin comes with a well-known risk: it can cause bleeding, particularly in the stomach and intestines. So the central question has always been whether the benefit of preventing heart attacks and strokes outweighs the risk of bleeding. According to an editorial by Lloyd-Jones DM, published in *JAMA Cardiology* on April 26, 2022, and summarized by the American College of Cardiology, the answer is not a simple "yes" for everyone. The editorial's central message is clear: aspirin therapy is not a one-size-fits-all treatment. It may offer benefit for some patients, while for others the risk–benefit ratio may not be favorable. ## The Early Promise of Aspirin: What Initial Studies Found For decades, aspirin was viewed as a powerful and inexpensive tool for heart disease prevention. Some of the most influential early studies seemed to support this view. The **Physicians' Health Study**, one of the first major randomized trials, showed that aspirin use in primary prevention reduced the risk of **myocardial infarction** (heart attack) among large populations of healthy male physicians. This finding helped establish the idea that aspirin could benefit many people. However, subsequent research complicated the picture. The **Women's Health Study**, another landmark trial, found **no reduction in major cardiovascular disease (CVD)** with primary prevention aspirin use among women. Interestingly, the study did show a **reduction in stroke risk** in the aspirin group. Taken together, these early trials suggested that the effects of aspirin might differ by sex and by the type of cardiovascular event, and that any benefits needed to be weighed carefully. One important finding from those early trials has never changed: aspirin consistently produced **small absolute increases in major bleeding risk**. In absolute terms, the increases were small, but they represented real harm for some people. ## The 2016 USPSTF Recommendations: Aspirin's Earlier Role Based on the evidence available at the time, the USPSTF issued recommendations in 2016 that were more favorable toward aspirin: - **Patients aged 50–59 years** at elevated cardiovascular risk who were not at risk for bleeding were recommended to start low-dose aspirin (a **Grade B recommendation**, meaning the USPSTF recommends the service with moderate-to-high certainty of net benefit). - **Patients aged 60–69 years** were offered a more individualized recommendation, with the decision left to the clinician and patient, again weighing cardiovascular risk against bleeding risk. - For patients younger than 50 or older than 69 years, the USPSTF concluded there was **insufficient evidence** to make a recommendation. At the time, this guidance seemed reasonable. But the landscape of cardiovascular prevention was about to change dramatically. ## The 2018 Landmark Trials: New Evidence Changes the Picture Over the past 30 years, large cardiovascular preventive efforts have greatly impacted public health. These include increasing use of **statin medications** to lower cholesterol and **antihypertensive medications** to control blood pressure, along with reductions in tobacco use. This means the "baseline" risk of cardiovascular events in modern populations is lower than in the older aspirin trials — leaving less room for aspirin to demonstrate additional benefit. In 2018, three key trials of primary prevention with aspirin were published. Together, they reshaped the scientific debate. ### ASPREE Trial: Risks in Healthy Older Adults The **ASPREE trial** enrolled healthy older patients aged 65 years and older. Participants received either low-dose daily aspirin or placebo. The results were striking and concerning: - **Mortality (death from any cause):** 5.9% in the aspirin group versus 5.2% in the placebo group at a median follow-up of 4.7 years — meaning aspirin was associated with an **increased risk of death**. - **Cancer mortality:** 3.1% with aspirin versus 2.3% with placebo, again favoring placebo. - **Major bleeding:** occurred at similar rates in both groups (0.3% in both groups). This was a sobering finding: in healthy older adults, daily aspirin did not protect against death and was associated with **higher overall and cancer-related mortality**. ### ASCEND Trial: Mixed Results in Diabetes Patients The **ASCEND trial** focused on patients with **diabetes**, a group already at higher cardiovascular risk. Participants were randomized to daily low-dose aspirin or placebo and followed for a mean of 7.4 years: - **Cardiovascular events reduced:** 8.5% in the aspirin group versus 9.6% in the placebo group — a meaningful reduction. - **But major bleeding increased:** 4.1% with aspirin versus 3.2% with placebo. The cardiovascular benefit was real, but it was largely offset by the increase in major bleeding. For patients with diabetes, the net benefit was therefore uncertain. ### ARRIVE Trial: No Significant Benefit, Doubled Bleeding The **ARRIVE trial** studied middle-aged and older adults at intermediate risk for **atherosclerotic cardiovascular disease (ASCVD)** — a condition where arteries become narrowed and hardened by cholesterol plaque — but who did not have diabetes. Key results at a median follow-up of 5 years: - **Cardiovascular events:** 4.29% in the aspirin group versus 4.48% in the placebo group — a **nonsignificant reduction**, meaning the difference could have been due to chance. - **Gastrointestinal bleeding nearly doubled:** 0.97% with aspirin versus 0.46% with placebo. In the ARRIVE trial, aspirin failed to provide a statistically meaningful benefit while notably increasing bleeding risk. ## The TIPS-3 Trial (2020): A Polypill Plus Aspirin Approach One more trial, published after the 2018 trio, added an important twist. The **TIPS-3 trial** (2020) enrolled patients at elevated risk for ASCVD who had **low baseline use** of statin and blood pressure medications. Participants were randomized to receive aspirin or placebo **in addition to a "polypill"** — a single combination pill containing a statin and antihypertensive medications. In this setting, aspirin showed a **significant reduction in cardiovascular events**: 4.1% in the aspirin group versus 5.8% in the placebo group over a mean follow-up of 4.6 years. This finding is important because it suggests that aspirin's benefit may be more evident in populations that have **less access to other preventive treatments**. In the 2018 trials, rates of statin and antihypertensive use were already quite high, and tobacco use was relatively low. As the editorial notes, there may be **less opportunity for primary prevention aspirin to demonstrate benefit** when other risk factors are already well controlled. ## The 2019 ACC/AHA Guidelines: A Shift Toward Caution In 2019, the American College of Cardiology (ACC), American Heart Association (AHA), and multispecialty organizations released updated primary prevention guidelines that reflected the mounting evidence: - Aspirin was classified as **Class III (harm)** for primary prevention in patients aged **70 years and older** — meaning the potential harms clearly outweigh any benefits, and the medication **should not be used** in this group. - For patients aged **40–70 years**, the recommendation strength was reduced to **Class IIb**, a "weak" recommendation indicating that the usefulness or effectiveness of aspirin is less well established. The guideline emphasized **individual decision-making**, weighing each patient's specific cardiovascular risk, bleeding risk, and preferences. This represented a major shift. Aspirin was no longer a "just in case" medication for older adults; it was now seen as a potential source of harm in that population. ## The 2021–2022 USPSTF Recommendation: The New Guidance Following these developments, the USPSTF issued its updated recommendation for 2021–2022, further narrowing the role of aspirin in primary prevention: - **Patients aged 40–59 years** at increased risk of cardiovascular disease (typically a 10% or higher 10-year risk) should make an **individualized decision** with their clinician about starting aspirin. This applies only to patients who are not at increased risk for bleeding and who have a life expectancy of at least 10 years. - **Patients aged 60 years and older:** the USPSTF now **discourages starting aspirin** for primary prevention, because the risk of bleeding outweighs the potential cardiovascular benefit. The difference from the 2016 guidance is significant. The age cutoff for regular use was lowered, and the recommendation for ages 60 and older flipped from "individualized" to "discouraged." The message to patients is simple: if you haven't had a heart attack or stroke and you're over 60, daily aspirin is likely doing more harm than good. ## Clinical Implications: What This Means for Patients If you or a loved one is currently taking daily aspirin for prevention, you may be wondering what to do. The first and most important point: **do not stop any medication without speaking to your doctor first**. Some people take aspirin because they have already had a heart attack, stroke, or a stent placed — this is **secondary prevention**, which is completely different. The new USPSTF guidance applies only to **primary prevention** — that is, people who have never experienced a cardiovascular event. For those individuals, the takeaway is: - The decision to start aspirin should be made **together with your healthcare provider**, considering your age, your calculated cardiovascular risk, your bleeding risk, your other medications, and your personal preferences. - For most people over 60, aspirin is likely to cause more harm than benefit in terms of primary prevention. - For people 40–59 at increased risk, aspirin may be helpful for some but not others — an individual risk discussion is essential. - If you have diabetes, the ASCEND trial shows aspirin can reduce heart attack and stroke risk, but this comes with an increased bleeding risk. This trade-off should be discussed explicitly with your doctor. It's also important to remember that aspirin is only one tool in the prevention toolkit. The broader impact on public health over the past 30 years has come primarily from **statins, blood pressure medications, and smoking cessation**. These interventions address the root causes of cardiovascular disease, whereas aspirin only addresses clot formation. ## Limitations: What This Guidance Can't Tell Us While the new USPSTF recommendation is based on the strongest evidence to date, important uncertainties remain: - The three major 2018 trials (ASPREE, ASCEND, ARRIVE) were each designed differently, with different patient populations, aspirin doses, and follow-up durations. Comparing them directly requires interpretation. - The ASPREE trial's surprising finding of increased cancer mortality with aspirin was not anticipated and has not been fully explained. It remains unclear whether this reflects a true effect or a chance finding. - The TIPS-3 trial suggests aspirin may be more beneficial in populations with limited access to statins and blood pressure medications. This means the "right" answer may depend on where you live and what other treatments are available to you. - The USPSTF guidance applies to typical adults and may not address specific high-risk groups, such as people with chronic kidney disease, familial hypercholesterolemia, or other conditions that elevate cardiovascular risk in ways not fully captured by standard risk calculators. - Gastrointestinal bleeding was the most commonly measured harm, but aspirin also raises the risk of hemorrhagic stroke (bleeding in the brain) and other serious bleeding events. These outcomes were less consistently reported across trials. No guideline can replace a thoughtful conversation between a patient and clinician. Your individual bleeding risk depends on factors such as age, kidney function, history of stomach ulcers, use of blood thinners or anti-inflammatory pain relievers (NSAIDs), and blood pressure control. These details matter enormously. ## Recommendations: Actionable Advice for Patients If you are considering starting — or continuing — daily aspirin for primary prevention, here are concrete steps you can take: 1. **Know your numbers.** Ask your doctor to calculate your 10-year ASCVD risk, which includes your age, sex, race, blood pressure, cholesterol levels, smoking status, and diabetes status. This is the single most important starting point. 1. **Ask about your bleeding risk.** Tell your doctor if you have a history of stomach ulcers, gastrointestinal bleeding, kidney disease, or bleeding disorders. Mention any medications that increase bleeding risk, including blood thinners, NSAIDs, steroids, and some herbal supplements. 1. **Discuss the evidence with your doctor.** Share your age and ask specifically whether the new USPSTF guidance applies to you. If you are 60 or older, expect that the recommendation may lean against starting aspirin for primary prevention. 1. **Don't stop aspirin suddenly.** If you are already taking aspirin and your doctor agrees it's no longer needed, discuss a safe plan for stopping. For secondary prevention (after a heart attack, stroke, or stent), aspirin is still recommended and should generally be continued indefinitely unless there is a strong reason to stop. 1. **Focus on proven prevention strategies.** Aspirin should never be a substitute for a heart-healthy lifestyle. Work on blood pressure control, cholesterol management with statins when indicated, smoking cessation, a balanced diet, and regular physical activity. These strategies have the largest impact on cardiovascular health. In summary, the new guidance reflects a maturing understanding: aspirin remains a powerful and life-saving medication for people who have already had cardiovascular events, but for primary prevention, its role is narrower, more selective, and carefully weighed against the harms. As the editorial's author, Geoffrey D. Barnes, MD, MSc, FACC, emphasizes, aspirin is not a one-size-fits-all therapy. The next time you see your doctor, make sure your aspirin decision is based on your personal risk profile — not on habits or advice from decades past. ## Frequently Asked Questions ### If I am over 60 and have never had a heart attack or stroke, should I stop taking daily aspirin? The updated USPSTF guidance discourages starting aspirin for primary prevention in adults aged 60 and older because the risk of bleeding outweighs the potential cardiovascular benefit. If you are already taking aspirin, do not stop suddenly. Talk with your doctor first to make a safe decision based on your personal health situation. ### What exactly is the difference between primary and secondary prevention of heart attack and stroke? Primary prevention means taking a medication to prevent a first heart attack or stroke in someone who has never had one. Secondary prevention is for people who have already had a heart attack, stroke, or stent placement. The new USPSTF guidance applies only to primary prevention. Aspirin remains recommended for secondary prevention. ### I already had a heart attack. Does the new guidance mean I should stop taking aspirin? No. The new USPSTF guidance applies only to primary prevention — people who have never had a cardiovascular event. If you have already had a heart attack, stroke, or stent, aspirin is considered secondary prevention. In that setting, aspirin is still recommended and should generally be continued indefinitely, but always discuss any changes with your doctor. ### Why did the advice about daily aspirin change so much? New evidence from 2018 trials, including ASPREE, ASCEND, and ARRIVE, showed that aspirin's benefit in primary prevention is smaller than previously thought. Meanwhile, the risk of serious bleeding remains. Modern treatments like statins and blood pressure medications have also lowered baseline heart risk, leaving less room for aspirin to help. The guidance now discourages aspirin for adults over 60. ### What are the main harms of taking daily aspirin? Aspirin can cause bleeding, especially in the stomach and intestines. It also raises the risk of hemorrhagic stroke. In the ARRIVE trial, gastrointestinal bleeding nearly doubled with aspirin. The ASPREE trial found increased death and cancer mortality in healthy older adults taking aspirin. These risks are why aspirin is no longer recommended for everyone. ### What should I ask my doctor before starting or continuing daily aspirin? Ask your doctor to calculate your 10-year ASCVD risk score, which includes age, blood pressure, cholesterol, smoking, and diabetes status. Ask about your personal bleeding risk, including history of ulcers, kidney disease, or use of blood thinners and NSAIDs. Also ask how the new USPSTF guidance applies to your age and whether you need aspirin at all. ### When should I seek a second opinion about starting or stopping daily aspirin for primary prevention of heart attack and stroke? Daily aspirin for primary prevention is no longer recommended for everyone. For adults 60 and older who have not had a heart attack or stroke, current guidance discourages starting it because bleeding risk outweighs possible benefit. For adults 40–59 at increased cardiovascular risk, the decision is individualized, considering age, bleeding risk, other medications, and preferences. If you are unsure whether aspirin is right for you, a second opinion can help you weigh these factors against the latest evidence. Diagnostic Detectives Network provides independent expert second opinions. ## Source Information **Original Article Title:** USPSTF Report on Aspirin for Primary Prevention - American College of Cardiology **Editorial Author:** Lloyd-Jones DM **Original Citation:** USPSTF Report on Aspirin for Primary Prevention. *JAMA Cardiol* 2022;Apr 26:[Epub ahead of print]. **Summary Author:** Geoffrey D. Barnes, MD, MSc, FACC **Publication Date:** April 26, 2022 **Clinical Topics Covered:** Dyslipidemia, Geriatric Cardiology, Prevention, Nonstatins, Novel Agents, Statins **Keywords:** Antihypertensive Agents, Aspirin, Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Gastrointestinal Hemorrhage, Geriatrics, Heart Disease Risk Factors, Hemorrhage, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Myocardial Infarction, Neoplasms, Primary Prevention, Public Health, Risk Assessment, Risk Factors, Stroke, Tobacco Use © 2023 American College of Cardiology Foundation. All rights reserved. *This patient-friendly article is based on peer-reviewed research and professionally authored summaries. It is for educational purposes only and is not a substitute for individualized medical advice. Always consult your physician about your specific health situation.* --- Publisher: Diagnostic Detectives Network (https://diagnosticdetectives.com) — independent multi-expert medical second opinions, worldwide, private-pay. Author byline: Anton Titov, MD, PhD. Contact: https://diagnosticdetectives.com/pages/contact Canonical page: https://diagnosticdetectives.com/products/daily-aspirin-for-heart-attack-and-stroke-prevention-understanding-the-new-uspstf-guidance